CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children
暂无分享,去创建一个
S. Spector | F. Aweeka | E. Capparelli | S. Nachman | A. Saitoh | A. Kovacs | S. Burchett | T. Fenton | A. Wiznia | Elizabeth Sarles
[1] S. Spector,et al. Efavirenz Pharmacokinetics in HIV-1-Infected Children Are Associated With CYP2B6-G516T Polymorphism , 2007, Journal of acquired immune deficiency syndromes.
[2] V. Natarajan,et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV‐infected patients in Uganda , 2007, HIV medicine.
[3] P. Binkley,et al. Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues , 2006, Pharmacogenetics and genomics.
[4] J. Haines,et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] M. Lederman,et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] M. Ingelman-Sundberg,et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz , 2006, Pharmacogenetics and genomics.
[7] K. Tashima,et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] M. Eichelbaum,et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz , 2005, Pharmacogenetics and genomics.
[9] M. Hirsch,et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. , 2005, The Journal of infectious diseases.
[10] S. Khoo,et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. , 2005, The Journal of antimicrobial chemotherapy.
[11] S. Khoo,et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus‐infected individuals , 2005, Clinical pharmacology and therapeutics.
[12] D. Mayers,et al. Appropriate use of nevirapine for long-term therapy. , 2005, The Journal of infectious diseases.
[13] G. Montepiedra,et al. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. , 2005, The Journal of infectious diseases.
[14] V. Soriano,et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] S. Spector,et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children , 2005, AIDS.
[16] C. Moore,et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.
[17] Amalio Telenti,et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.
[18] Catia Marzolini,et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.
[19] S. Hammer,et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. , 2004, The New England journal of medicine.
[20] S. Oka,et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. , 2004, Biochemical and biophysical research communications.
[21] Dorothy Bray,et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial , 2003, The Lancet.
[22] S. Hayashi,et al. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. , 2003, Pediatrics.
[23] A. Badley,et al. Induction of Apoptosis by a Nonnucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor , 2002, Antimicrobial Agents and Chemotherapy.
[24] D. Greenblatt,et al. Differential Modulation of P-Glycoprotein Expression and Activity by Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors in Cell Culture , 2002, Pharmaceutical Research.
[25] R. de Groot,et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. , 2002, The Lancet. Infectious diseases.
[26] Jacques Fellay,et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.
[27] U. Hofmann,et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.
[28] R H Levy,et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[29] Dorothy Bray,et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial , 1999, The Lancet.
[30] T. Macgregor,et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[31] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.